Literature DB >> 30535998

BH3 Profiling: A Functional Assay to Measure Apoptotic Priming and Dependencies.

Cameron Fraser1,2, Jeremy Ryan3, Kristopher Sarosiek4,5.   

Abstract

Apoptosis (programmed cell death) is activated by a wide variety of cellular stresses or insults and is vital for proper mammalian development as well as the maintenance of organismal homeostasis. The apoptosis pathway is also engaged by many common types of anticancer therapies and ionizing radiation, which contributes to the regressions of tumors or the toxic side effects of treatment. Due to the importance of maintaining healthy cell survival or the efficient clearance of cancer cells, the BH3 profiling assay was developed to functionally measure the state of the apoptosis pathway in any given cells. This assay involves the exposure of cellular mitochondria, where the BCL-2 family of proteins resides and controls the commitment to apoptosis, to proapoptotic BH3 peptides that mimic the activity of endogenous proapoptotic proteins. By using either activator or sensitizer peptides, the level of mitochondrial apoptotic priming (proximity to the threshold at which a cell commits to cell death) or dependence on prosurvival BCL-2 family proteins can be determined. Described here are two methods of BH3 profiling that can enable a user to make these functional measurements, which can be useful for predicting cellular responses to proapoptotic stressors or therapeutics (BH3 mimetics) that inhibit the activity of prosurvival proteins.

Entities:  

Keywords:  BCL-2 family; Chemotherapeutics; MOMP; Mitochondrial apoptotic priming

Mesh:

Substances:

Year:  2019        PMID: 30535998      PMCID: PMC7325165          DOI: 10.1007/978-1-4939-8861-7_4

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  17 in total

Review 1.  How do Bax and Bak lead to permeabilization of the outer mitochondrial membrane?

Authors:  Antonella Antignani; Richard J Youle
Journal:  Curr Opin Cell Biol       Date:  2006-10-12       Impact factor: 8.382

Review 2.  The BCL-2 protein family: opposing activities that mediate cell death.

Authors:  Richard J Youle; Andreas Strasser
Journal:  Nat Rev Mol Cell Biol       Date:  2008-01       Impact factor: 94.444

Review 3.  Mitochondrial regulation of cell death.

Authors:  Stephen W G Tait; Douglas R Green
Journal:  Cold Spring Harb Perspect Biol       Date:  2013-09-01       Impact factor: 10.005

Review 4.  Mitochondria: gatekeepers of response to chemotherapy.

Authors:  Kristopher A Sarosiek; Triona Ni Chonghaile; Anthony Letai
Journal:  Trends Cell Biol       Date:  2013-09-21       Impact factor: 20.808

5.  Tight Sequestration of BH3 Proteins by BCL-xL at Subcellular Membranes Contributes to Apoptotic Resistance.

Authors:  Jessie Pécot; Laurent Maillet; Janic Le Pen; Céline Vuillier; Sophie de Carné Trécesson; Aurélie Fétiveau; Kristopher A Sarosiek; Florian J Bock; Frédérique Braun; Anthony Letai; Stephen W G Tait; Fabien Gautier; Philippe P Juin
Journal:  Cell Rep       Date:  2016-12-20       Impact factor: 9.423

Review 6.  Many players in BCL-2 family affairs.

Authors:  Tudor Moldoveanu; Ariele Viacava Follis; Richard W Kriwacki; Douglas R Green
Journal:  Trends Biochem Sci       Date:  2014-02-03       Impact factor: 13.807

7.  tBID, a membrane-targeted death ligand, oligomerizes BAK to release cytochrome c.

Authors:  M C Wei; T Lindsten; V K Mootha; S Weiler; A Gross; M Ashiya; C B Thompson; S J Korsmeyer
Journal:  Genes Dev       Date:  2000-08-15       Impact factor: 11.361

8.  BID preferentially activates BAK while BIM preferentially activates BAX, affecting chemotherapy response.

Authors:  Kristopher A Sarosiek; Xiaoke Chi; John A Bachman; Joshua J Sims; Joan Montero; Luv Patel; Annabelle Flanagan; David W Andrews; Peter Sorger; Anthony Letai
Journal:  Mol Cell       Date:  2013-09-26       Impact factor: 17.970

9.  Relative mitochondrial priming of myeloblasts and normal HSCs determines chemotherapeutic success in AML.

Authors:  Thanh-Trang Vo; Jeremy Ryan; Ruben Carrasco; Donna Neuberg; Derrick J Rossi; Richard M Stone; Daniel J Deangelo; Mark G Frattini; Anthony Letai
Journal:  Cell       Date:  2012-10-12       Impact factor: 41.582

10.  BID-induced structural changes in BAK promote apoptosis.

Authors:  Tudor Moldoveanu; Christy R Grace; Fabien Llambi; Amanda Nourse; Patrick Fitzgerald; Kalle Gehring; Richard W Kriwacki; Douglas R Green
Journal:  Nat Struct Mol Biol       Date:  2013-04-21       Impact factor: 15.369

View more
  10 in total

1.  Age-dependent regulation of SARS-CoV-2 cell entry genes and cell death programs correlates with COVID-19 severity.

Authors:  Zintis Inde; Ben A Croker; Clarence Yapp; Gaurav N Joshi; Johan Spetz; Cameron Fraser; Xingping Qin; Le Xu; Brian Deskin; Elisa Ghelfi; Gabrielle Webb; Aaron F Carlin; Yanfang Peipei Zhu; Sandra L Leibel; Aaron F Garretson; Alex E Clark; Jason M Duran; Victor Pretorius; Laura E Crotty-Alexander; Chendi Li; Jamie Casey Lee; Chhinder Sodhi; David J Hackam; Xin Sun; Aaron N Hata; Lester Kobzik; Jeffrey Miller; Jin-Ah Park; Douglas Brownfield; Hongpeng Jia; Kristopher A Sarosiek
Journal:  Sci Adv       Date:  2021-08-18       Impact factor: 14.136

2.  BH3 profiling discriminates the anti‑apoptotic status of 5‑fluorouracil‑resistant colon cancer cells.

Authors:  Kazuma Ishikawa; Yutaka Kawano; Yohei Arihara; Tomohiro Kubo; Kohichi Takada; Kazuyuki Murase; Koji Miyanishi; Masayoshi Kobune; Junji Kato
Journal:  Oncol Rep       Date:  2019-10-15       Impact factor: 3.906

3.  WEE1 Inhibition Enhances Anti-Apoptotic Dependency as a Result of Premature Mitotic Entry and DNA Damage.

Authors:  Mathilde Rikje Willemijn de Jong; Myra Langendonk; Bart Reitsma; Pien Herbers; Marcel Nijland; Gerwin Huls; Anke van den Berg; Emanuele Ammatuna; Lydia Visser; Tom van Meerten
Journal:  Cancers (Basel)       Date:  2019-11-07       Impact factor: 6.639

Review 4.  BH3-mimetics: recent developments in cancer therapy.

Authors:  Paul A Townsend; Maria V Kozhevnikova; Olivier N F Cexus; Andrey A Zamyatnin; Surinder M Soond
Journal:  J Exp Clin Cancer Res       Date:  2021-11-09

5.  Dynamic regulation of P-TEFb by 7SK snRNP is integral to the DNA damage response to regulate chemotherapy sensitivity.

Authors:  Yin Fang; Yan Wang; Benjamin M Spector; Xue Xiao; Chao Yang; Ping Li; Yuan Yuan; Ping Ding; Zhi-Xiong Xiao; Peixuan Zhang; Tong Qiu; Xiaofeng Zhu; David H Price; Qintong Li
Journal:  iScience       Date:  2022-08-04

6.  Small molecule SJ572946 activates BAK to initiate apoptosis.

Authors:  Giridhar Sekar; Geetika Singh; Xingping Qin; Cristina D Guibao; Brittany Schwam; Zintis Inde; Christy R Grace; Weixing Zhang; P Jake Slavish; Wenwei Lin; Taosheng Chen; Richard E Lee; Zoran Rankovic; Kristopher Sarosiek; Tudor Moldoveanu
Journal:  iScience       Date:  2022-09-06

7.  Exploiting endogenous and therapy-induced apoptotic vulnerabilities in immunoglobulin light chain amyloidosis with BH3 mimetics.

Authors:  Cameron S Fraser; Johan K E Spetz; Xingping Qin; Adam Presser; Jonathan Choiniere; Chendi Li; Stacey Yu; Frances Blevins; Aaron N Hata; Jeffrey W Miller; Gary A Bradshaw; Marian Kalocsay; Vaishali Sanchorawala; Shayna Sarosiek; Kristopher A Sarosiek
Journal:  Nat Commun       Date:  2022-10-02       Impact factor: 17.694

8.  Mitochondrial estrogen receptors alter mitochondrial priming and response to endocrine therapy in breast cancer cells.

Authors:  Bahriye Karakas; Yeliz Aka; Asli Giray; Sehime Gulsun Temel; Ufuk Acikbas; Huveyda Basaga; Ozgur Gul; Ozgur Kutuk
Journal:  Cell Death Discov       Date:  2021-07-22

9.  Age-dependent regulation of SARS-CoV-2 cell entry genes and cell death programs correlates with COVID-19 disease severity.

Authors:  Zintis Inde; Clarence Yapp; Gaurav N Joshi; Johan Spetz; Cameron Fraser; Brian Deskin; Elisa Ghelfi; Chhinder Sodhi; David Hackam; Lester Kobzik; Ben Croker; Douglas Brownfield; Hongpeng Jia; Kristopher A Sarosiek
Journal:  bioRxiv       Date:  2020-09-13

10.  Discovery of Small Molecule Bak Activator for Lung Cancer Therapy.

Authors:  Dongkyoo Park; Abu Syed Md Anisuzzaman; Andrew T Magis; Guo Chen; Maohua Xie; Guojing Zhang; Madhusmita Behera; Gabriel L Sica; Suresh S Ramalingam; Taofeek K Owonikoko; Xingming Deng
Journal:  Theranostics       Date:  2021-07-25       Impact factor: 11.556

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.